Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ASP Isotopes (ASPI) Cash & Equivalents (2022 - 2025)

ASP Isotopes has reported Cash & Equivalents over the past 4 years, most recently at $285.6 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 361.4% to $285.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $285.6 million, a 361.4% increase, with the full-year FY2025 number at $285.6 million, up 361.4% from a year prior.
  • Cash & Equivalents reached $285.6 million in Q4 2025 per ASPI's latest filing, up from $113.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $285.6 million in Q4 2025, with the low at $431565.0 in Q3 2022.
  • The 4-year median for Cash & Equivalents is $15.9 million (2023), against an average of $44.8 million.
  • Peak YoY movement for Cash & Equivalents: increased 28.89% in 2023, then surged 2155.18% in 2024.
  • Tracing ASPI's Cash & Equivalents over 4 years: stood at $2.4 million in 2022, then soared by 231.0% to $7.9 million in 2023, then soared by 682.63% to $61.9 million in 2024, then skyrocketed by 361.4% to $285.6 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $285.6 million, $113.9 million, and $67.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.